US 12263227
Optimized mRNA encoding CAS9 for use in LNPs
granted A61KA61K48/0025A61K9/1271
Quick answer
US patent 12263227 (Optimized mRNA encoding CAS9 for use in LNPs) held by CRISPR THERAPEUTICS AG expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- CRISPR THERAPEUTICS AG
- Grant date
- Tue Apr 01 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 18
- CPC classes
- A61K, A61K48/0025, A61K9/1271